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Arsenic is a ubiquitous element in the environ-
ment, with metalloid properties. In many parts
of the world, arsenic is present in drinking water
from wells drilled in ground strata containing
the element (IARC 1980; WHO 1981). It is
also widely present in the groundwater supply
in the United States (Welch et al. 1999).
Long-term exposure to ingested arsenic
may induce many health effects. Biologic gra-
dients between ingested arsenic and skin and
various internal cancers have been well-docu-
mented and used to derive the maximum
contamination level of arsenic in drinking
water by the U.S. Environmental Protection
Agency (Chen et al. 1988a, 1997b; Morales
et al. 2000; Tsai et al. 1998). Other chronic
health effects induced by arsenic have also
drawn global attention, especially cardiovas-
cular, neurologic, reproductive, and develop-
mental hazards (Chen et al. 1997a, 1999).
Mortality and morbidity of vascular diseases,
including peripheral vascular disease, cerebral
infarction, and ischemic heart disease, have
been documented to be associated with arsenic
levels in drinking water in the arseniasis-
endemic area (Chen et al. 1988b, 1996; Chiou
et al. 1997b; Tseng et al. 1996; Wang et al.
2002; Wu et al. 1989). The associations
between long-term exposure to arsenic and
microvascular diseases, including renal dis-
ease, retinopathy, and neuropathy, remain to
be elucidated. Epidemiologic studies have
shown a dose–response relationship between
arsenic in drinking water and prevalence and
mortality of diabetes mellitus in southwestern
Taiwan (Lai et al. 1994; Tsai et al. 1999).
Similar findings have been reported in
Sweden (Rahman and Axelson 1995;
Rahman et al. 1995), Bangladesh (Rahman et
al. 1998), and the United States (Lewis
1999). In Taiwan, the incidence of diabetes
mellitus was reported to be three to ﬁve times
higher among residents in the southwestern
arseniasis-endemic area compared with those
in a nonendemic area (Tseng et al. 2000;
Wang et al. 1997). However, no studies have
been done to differentiate types of diabetes
mellitus associated with arsenic. Diabetes
mellitus has been documented to induce
stroke, ischemic heart disease, peripheral vas-
cular disease, nephropathy, retinopathy, and
neuropathy through both macrovascular and
microvascular damage (Chait and Bierman
1994; King and Banskota 1994; Krolewski et
al. 1994). It remains to be revealed whether
the prevalence of vascular diseases of diabetics
is different between arsenic-exposed and unex-
posed groups. The interactive effects of arsenic
and diabetes mellitus on micro- and macrovas-
cular diseases should be closely examined.
Medical records for more than a million
individuals in 1999–2000 have been released
from the National Health Insurance for acad-
emic research in Taiwan. We used this data-
base to estimate prevalence of non-insulin-
dependent diabetes mellitus and its related
vascular diseases in arseniasis-endemic and
nonendemic areas in Taiwan.
Materials and Methods
National Health Insurance Database. In this
study we used individual-based reimbursement
claims randomly selected from the National
Health Insurance Database, which was col-
lected by the Bureau of National Health
Insurance and compiled by the National
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There is evidence indicating that ingestion of arsenic may predispose the development of diabetes
mellitus in arsenic-endemic areas in Taiwan. However, the prevalence of diabetes and related vas-
cular diseases in the entire southwestern arseniasis-endemic and nonendemic areas remains to be
elucidated. We used the National Health Insurance Database for 1999–2000 to derive the preva-
lence of non-insulin-dependent diabetes and related vascular diseases by age and sex among resi-
dents in southwestern arseniasis-endemic and nonendemic areas in Taiwan. The study included
66,667 residents living in endemic areas and 639,667 in nonendemic areas, all ≥ 25 years of age.
The status of diabetes and vascular diseases was ascertained through disease diagnosis and treat-
ment prescription included in the reimbursement claims of clinics and hospitals. The prevalence
of non-insulin-dependent diabetes, age- and gender-adjusted to the general population in Taiwan,
was 7.5% (95% confidence interval, 7.4–7.7%) in the arseniasis-endemic areas and 3.5%
(3.5–3.6%) in the nonendemic areas. Among both diabetics and nondiabetics, higher prevalence
of microvascular and macrovascular diseases was observed in arseniasis-endemic than in the
nonendemic areas. Age- and gender-adjusted prevalence of microvascular disease in endemic and
nonendemic areas was 20.0% and 6.0%, respectively, for diabetics, and 8.6% and 1.0%, respec-
tively, for nondiabetics. The corresponding prevalence of macrovascular disease was 25.3% and
13.7% for diabetics, and 12.3% and 5.5% for nondiabetics. Arsenic has been suggested to increase
the risk of non-insulin-dependent diabetes mellitus and its related micro- and macrovascular dis-
eases. Key words: arsenic, diabetic complications, environmental health, epidemiology, health
insurance, non-insulin-dependent diabetes mellitus, vascular diseases. Environ Health Perspect
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National Health Insurance in Taiwan is 
compulsory and universal and provides com-
prehensive health benefits (Chiang 1997).
Since 1995, more than 96% of the total 
population of Taiwan has been covered by 
the National Health Insurance system
[Department of Health (DOH) 1995–1999].
Ninety-three percent of all health providers
have been contracted to the Bureau of
National Health Insurance, and those not
contracted provide much fewer health services
[DOH and British Columbia Ministry of
Health (BCMH) 1999]. The copayment rate
for patients is as low as 8–20%, with a ﬁxed
charge of $1.40 U.S. Thus, almost all the peo-
ple, particularly those affected with chronic
diseases, have been using the contracted health
providers (Cheng and Chiang 1997). More
than 96% of the population, in different age
and gender groups, who were covered by
National Health Insurance have used health
services at least once through contracted
health providers during 1999–2000 (DOH
2002). Therefore, the information from the
National Health Insurance Database is con-
sidered appropriate to derive accurate preva-
lence rates of chronic diseases such as diabetes
mellitus and vascular diseases.
In this study, we used individual-based
reimbursement claims from the data file of
clinical diagnosis and treatment and the data
ﬁle of medical prescriptions. The diagnosis of
disease status was made from International
Classification of Diseases, Revision 9 (ICD-9)
codes recorded in the clinical diagnosis and
treatment and from drug names in the medical
prescriptions. 
In Taiwan, insulin-dependent diabetes
mellitus is classified as a severe disease. A
severe disease card is issued to people with
such diseases, which entitles patients to free
medical treatment. We used the data file of
patients with severe disease cards to exclude
insulin-dependent diabetics from all diabetic
patients. The diabetics in this study all had
the non-insulin-dependent type.
Southwestern arseniasis-endemic area.
The study population in the endemic area
included all those who have lived in four
southwestern townships: Puttee and Ichu of
Chimayo County and Peimen and Hsuehchia
of Taiwan County. The water from a large
proportion of artesian wells in these four
townships had arsenic concentrations > 0.35
mg/L according to a national survey of more
than 90% of wells in Taiwan (Chang et al.
1991). This arseniasis-endemic area has been
described in detail in a previous report (Chen
et al. 1988b). A total of 66,667 residents ≥ 25
years of age in the arseniasis-endemic area
were included in this study.
Nonendemic area. Taiwan has 323 rural
and urban townships and metropolitan
precincts. In this study, the nonendemic area
included 313 of them, excluding four town-
ships in the above-deﬁned arseniasis-endemic
area and another six neighboring townships:
Liuchiao of Chimayo County and Hsinying,
Hsiaying, Anting, Chiang-chun, and Yenshui
of Taiwan County. Because some artesian
wells have arsenic concentrations > 0.35 mg/L
and because a few cases of blackfoot disease
were identified in these neighboring town-
ships, they were excluded to deﬁne the nonen-
demic area more appropriately. Because the
complete ﬁles from the original database dur-
ing 1999–2000 were too large to be managed
and analyzed, the National Health Insurance
released a sampled database for research use, in
which a proportional systematic sampling was
used to retrieve one in every 500 records from
the two original reimbursement data files. A
total of 639,667 residents ≥ 25 years of age in
nonendemic area were included in this study.
Disease ascertainment. Diabetics were
deﬁned as patients diagnosed with an ICD-9
code of 250 or an ICD-9 A-code (abridged
code) of A181. Both microvascular and
macrovascular diseases related to diabetes mel-
litus were also defined by the ICD-9 codes
indicated in data ﬁles. The microvascular dis-
eases included renal diseases (ICD-9 codes
250.3, 581.8, 582.8, 583.8, 585.0, and
586.0), retinopathy (ICD-9 codes 250.4,
362.0, 362.01, 362.02, and 366.4), and neu-
ropathy (ICD-9 codes 250.5, 357.2, 358.1,
and 355). The macrovascular diseases included
coronary artery diseases (ICD-9 codes 410 and
411–414), cerebrovascular diseases (ICD-9
codes 430–438), and peripheral vascular dis-
eases (ICD-9 codes 250.6, 785.4, 443.8).
Statistical methods. The prevalence of dia-
betes mellitus and vascular diseases was first
derived for speciﬁc age and gender groups by
dividing the number of persons with a claim
for a given disease by the number of persons
with at least one reimbursement claim in
1999–2000. The direct method was used to
calculate age-adjusted, gender-adjusted, and
age- and gender-adjusted prevalence of the dis-
eases. The general population in midyear 2000
in Taiwan was used as standard population for
age and gender adjustment. Prevalence odds
ratios and their 95% conﬁdence intervals (CIs)
were calculated to indicate the association
between arsenic exposure and prevalence of
diabetes and vascular diseases.
Results
Prevalence of diabetes mellitus. There was an
increasing trend of diabetes mellitus preva-
lence with age in both arseniasis-endemic and
nonendemic areas, as shown in Table 1. The
prevalence in the arseniasis-endemic area was
consistently greater than in the nonendemic
area across all five age groups for both men
and women. The prevalence odds ratios of
diabetes in the endemic area in comparison
with the nonendemic area were consistently
greater in women than in men for all age
groups, as shown in Figure 1. After adjust-
ment for age and sex, the prevalence odds
ratio was 2.69 (95% CI, 2.65–2.73) in the
arseniasis-endemic area, using the non-
endemic area as the referent.
Prevalence of vascular diseases in diabet-
ics and nondiabetics. An increasing trend
with age for microvascular disease prevalence
was observed among diabetics and nondia-
betics in both arseniasis-endemic and non-
endemic areas for both men and women, as
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Table 1. Prevalence of diabetes mellitus (%) by age and sex in southwestern arseniasis-endemic and nonendemic areas in Taiwan.
Arseniasis-endemic area Nonendemic areas
Male Female Gender-adjusted Male Female Gender-adjusted
Age (years) Prevalence (n)P revalence (n)p revalence (95% CI) Prevalence (n)P revalence (n) prevalence (95% CI)
25–34 1.08 (7,892) 1.89 (7,362) 1.48 (1.29–1.67) 0.60 (40,535) 0.29 (78,438) 0.45 (0.41–0.49)
35–44 3.77 (8,148) 2.89 (7,170) 3.34 (3.06–3.64) 2.22 (54,509) 1.04 (79,860) 1.64 (1.57–1.71)
45–54 10.04 (5,667) 9.25 (5,776) 9.65 (9.11–10.19) 5.59 (47,129) 3.63 (70,557) 4.62 (4.50–7.88)
55–64 14.43 (5,781) 15.77 (6,543) 15.1 (14.48–15.74) 7.82 (43,451) 7.63 (59,373) 7.72 (7.56–7.89)
≥ 65 15.38 (5,644) 21.18 (6,684) 18.13 (17.45–18.81) 7.28 (85,442) 8.90 (80,353) 8.05 (7.92–8.18)
Age-adjusted prevalence 7.18 (6.92–7.44) 7.92 (7.66–8.18) 7.54 (7.35–7.73) 3.82 (3.75–3.89) 3.21 (3.16–3.26) 3.52 (3.48–3.56)
(95% CI)
Figure 1. Prevalence odds ratios for diabetes melli-
tus in arseniasis-endemic versus nonendemic
areas, by age and sex. Error bars indicate 95% CI.
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Gender-adjustedshown in Table 2. For all five age groups in
both men and women, the prevalence of
microvascular diseases was consistently high-
est among diabetics in the arseniasis-endemic
area, followed by nondiabetics in the endemic
area, diabetics in the nonendemic area, and
nondiabetics in the nonendemic area. Similar
findings were observed for macrovascular
diseases (Table 3): diabetics in the arseniasis-
endemic area had the highest prevalence, fol-
lowed by diabetics in nonendemic area,
nondiabetics in endemic area, and nondiabetics
in nonendemic area for most age groups in
men and women. Figure 2 shows the preva-
lence odds ratios of microvascular diseases
among diabetics of the endemic area (using the
55–64 age range as a typical example, the odds
ratio is 15.6; 95% CI, 13.4–18.0), nondiabetics
of the endemic area (7.0; 95% CI, 6.3–7.9),
and diabetics of the nonendemic area (5.1;
95% CI, 4.4–5.9) in comparison with nondia-
betics of the nonendemic area. The odds ratios
tended to be higher in women than in men
before 65 years of age but without statistical
signiﬁcance. Figure 3 illustrates the prevalence
odds ratios of macrovascular diseases in the
four diabetes-area groups by age and sex. The
prevalence odds ratios increased from non-
diabetics in the nonendemic area (for ages
55–64), to nondiabetics in the endemic area
(2.0; 95% CI, 1.9–2.2), to diabetics in the
nonendemic area (1.7; 95% CI, 1.6–1.8), to
diabetics in the endemic area (3.7; 95% CI,
3.3–4.0) for most age groups in men and
women. The odds ratios tended to be higher
in women than in men before 65 years of age,
with statistical signiﬁcance.
The prevalence of various vascular diseases
among diabetics and nondiabetics in endemic
and nonendemic areas is shown in Table 4.
The prevalence of all vascular diseases studied
was much higher among diabetics than among
nondiabetics and significantly higher in the
arseniasis-endemic area than in the nonen-
demic area. The prevalence odds ratios of these
vascular diseases in the arseniasis-endemic area
compared with the nonendemic area ranged
from 1.22 (95% CI, 1.10–1.35) for peripheral
vascular disease to 7.21 (95% CI, 6.51–7.97)
for neurologic disorder among diabetics, and
from 1.34 (95% CI, 1.29–1.39) for coronary
heart disease to 13.97 (95% CI, 13.38–14.58)
for neurologic disorder among diabetics.
Discussion
This study confirmed the findings of our 
previous study (Lai et al. 1994) in which the
subjects in the arseniasis-endemic area had an
elevated prevalence of diabetes compared with
the nonendemic area (odds ratio = 2.7 after
adjustment for age and sex). In this study we
found that women tended to have a higher
prevalence of diabetes than did men in the arse-
niasis-endemic area but not in the nonendemic
area. Furthermore, in the arseniasis-endemic
area, women had a statistically significantly
higher age-adjusted prevalence of vascular dis-
eases than did men (9.4% vs. 7.8% for
microvascular disease and 13.3% vs. 11.3% for
macrovascular disease) among the nondiabetics.
Also, women have been found to drink less
water than men. The hypothesis of a greater
vulnerability to arsenic exposure in women
than in men needs further investigation.
In a national diabetes survey (Pan et al.
1998) applying both fasting glucose and oral
glucose tolerance tests, the diabetes prevalence
for men ≥ 65 years of age in Taiwan was 7.6%.
The diabetes prevalence for the same age group
of men in this study was 8.1%, which is simi-
lar to that observed by Pan et al. (1998). The
diabetes prevalence was also compatible with
that observed in the United States [National
Health and Nutrition Examination Survey
(NHANES)] (Harris et al. 1987) and in Japan
(Kuzuya 1994). Diabetes prevalence by age
and sex in the southwestern arseniasis-endemic
area in this study is also similar to that
observed in a previous survey conducted in the
same endemic area (Lai et al. 1994).
Arsenic has been proposed to induce
insulin-dependent and non-insulin-dependent
diabetes, probably through increased oxidative
stress (Longnecker and Daniels 2001; Wu et
al. 2001). Oxidative stress has been found to
induce the development of insulin resistance
and endothelial dysfunction by the observa-
tions of normal, impaired glucose-tolerant,
and diabetic subjects (Gopaul et al. 2001).
Hypertension, an important component of
insulin resistance syndrome, has also been
found to be associated with long-term
ingested arsenic exposure (Chen et al. 1995).
It is essential to evaluate insulin secretion and
insulin sensitivity in subjects with various
degrees of arsenic exposure, taking genetic sus-
ceptibility (Chiou et al. 1997a) into account.
Phenylarsine oxide binding to sulfhydryl
groups (–SH) has been found to induce
insulin resistance (Frost and Lane 1985;
(Henriksen and Holloszy 1990) via the
increase of cell stress and reduction of glucose
Articles | Diabetes and vascular diseases related to arsenic
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Table 2. Prevalence of microvascular diseases (%) by age and sex among diabetics and nondiabetics in
the southwestern arseniasis-endemic and nonendemic areas in Taiwan.
Arseniasis-endemic area Nonendemic area
Diabetics Nondiabetics Diabetics Nondiabetics
Sex, age (years) Prevalence (n)P revalence (n)P revalence (n)P revalence (n)
Male
25–34 9.41 (85) 4.98 (7,807) 3.72 (242) 0.79 (40,293)
35–44 18.89 (307) 7.21 (7,841) 5.95 (1,210) 0.99 (53,299)
45–54 20.56 (569) 9.06 (5,098) 6.11 (2,633) 1.23 (44,496)
55–64 23.14 (834) 10.47 (4,947) 7.56 (3,398) 1.49 (40,053)
≥ 65 25.23 (868) 10.01 (4,776) 7.45 (6,218) 1.52 (79,224)
Age-adjusted prevalence (95% CI) 18.08 (15.86–20.30) 7.75 (7.45–8.05) 5.78 (5.71–6.55) 1.12 (1.08–1.16)
Female
25–34 14.39 (139) 6.49 (7,223) 5.75 (226) 0.47 (78,212)
35–44 24.15 (207) 9.36 (6,963) 5.52 (833) 0.78 (79,027)
45–54 23.41 (534) 10.91 (5,242) 7.03 (2,562) 1.10 (67,995)
55–64 27.13 (1,032) 11.74 (5,511) 7.35 (4,523) 1.46 (54,841)
≥ 65 25.00 (1,416) 11.03 (5,268) 7.07 (7,155) 1.64 (73,198)
Age-adjusted prevalence (95% CI) 21.87 (19.47–24.27) 9.42 (9.09–9.75) 6.31 (5.36–7.26) 0.96 (0.93–0.99)
Age and gender-adjusted  19.95 (18.31–21.58) 8.57 (8.35–8.80) 6.04 (5.44–6.65) 1.04 (1.01–1.07)
prevalence (95% CI)
Table 3. Prevalence of macrovascular diseases (%) by age and gender among diabetics and nondiabetics
in southwestern arseniasis-endemic and nonendemic areas in Taiwan.
Arseniasis-endemic area Nonendemic area
Diabetics Nondiabetics Diabetics Nondiabetics
Sex, age (years) Prevalence (n)P revalence (n)P revalence (n)P revalence (n)
Male
25–34 12.94 (85) 5.15 (7,807) 7.85 (242) 2.35 (40,293)
35–44 14.33 (307) 6.50 (7,841) 10.33 (1,210) 3.80 (53,299)
45–54 26.89 (569) 10.47 (5,098) 15.46 (2,633) 6.71 (44,496)
55–64 36.09 (834) 16.76 (4,947) 19.98 (3,398) 9.83 (40,053)
≥ 65 45.51 (868) 28.75 (4,776) 25.84 (6,218) 13.46 (79,224)
Age-adjusted prevalence (95% CI) 23.42 (21.03–25.81) 11.31 (10.97–11.65) 14.02 (12.94–15.10) 6.07 (5.98–6.16)
Female
25–34 21.58 (139) 9.80 (7,223) 7.08 (226) 1.64 (78,212)
35–44 16.91 (207) 7.42 (6,963) 10.08 (833) 2.62 (79,027)
45–54 28.09 (534) 10.97 (5,242) 14.75 (2,562) 4.68 (67,995)
55–64 38.28 (1,032) 19.00 (5,511) 19.66 (4,532) 8.02 (54,841)
≥ 65 47.74 (1,416) 30.30 (5,268) 25.13 (7,155) 12.91 (73,198)
Age-adjusted prevalence (95% CI) 27.13 (24.65–29.61) 13.25 (12.88–13.62) 13.40 (12.29–14.51) 4.81 (4.74–4.88)
Age and gender-adjusted  25.25 (23.53–26.97) 12.26 (12.01–12.51) 13.72 (12.95–14.49) 5.45 (5.39–5.51)
prevalence (95% CI)transport proteins, especially for GLUT4 and
GLUT1, and glucose uptake (Jhun et al.
1991). However, phenylarsine oxide is an arti-
ﬁcial organic form of arsenic used mainly for
testing the role of the sulfhydryl group in
insulin resistance. The use of natural arsenic
compounds such as arsenite, arsenate, and/or
methylated forms for such studies has been
suggested. There are no consistent changes in
glucose levels in experimental studies. Plasma
glucose and triglycerides were the lowest in
mice with high arsenate exposure administered
via drinking water (Hughes and Thompson
1996). Enhanced glucose uptake was found in
response to arsenite (100 µM for up to 180
min) in bovine chromafﬁn cells (Fladeby and
Serck-Hanssen 1999). Nonetheless, intraperi-
toneal administration of sodium arsenite of 1.0
mg/kg has been found to cause significantly
higher blood glucose in guinea pigs at 1 and 2
hr (Mitchell et al. 2000). Organic arsenic was
found to induce the inhibition of glucose
uptake (Liebl et al. 1995). Studies using long-
term treatment of well-speciﬁed arsenic species
are necessary for future conclusions. Arsenic-
induced oxidative stress, mainly through the
depletion of glutathione (Suzuki et al. 2001),
has been proposed to cause both insulin resis-
tance and atherosclerosis (del Razo et al.
2001), and the latter may be profound in
hyperglycemia or diabetic states (Curcio and
Ceriello 1992; Lorenzi 1992).
The finding of a strikingly increased
prevalence of macrovascular diseases observed
in the arseniasis-endemic area compared with
the nonendemic area is consistent with our pre-
vious ﬁndings of arsenic-induced atherosclerosis
(Chen et al. 1988b, 1996; Chiou et al. 1997b;
Tseng et al. 1996; Wang et al. 2002; Wu et al.
1989). There have been few studies comparing
the prevalence of speciﬁc vascular diseases in
relation to arsenic exposure in diabetics and
nondiabetics. Age-adjusted prevalence of cere-
brovascular disease in the Lanyang Basin, a
recently identiﬁed northeastern endemic area of
arseniasis in Taiwan, was 15.8% for men and
13.2% for women (Chiou et al. 1997b). The
two ﬁgures were between those found in the
present study: 21.4% for diabetics and 8.7%
for nondiabetics. Diabetes was associated with
an increased risk of cerebrovascular disease
showing an age- and gender-adjusted odds ratio
of 1.8 in the northeastern endemic area and 2.4
(21.35 ÷ 8.72) in the southwestern endemic
area of this study. A previous study showed a
dose–response relationship between ingested
arsenic and peripheral vascular diseases (Wang
et al. 2002). The present study demonstrated
the odds ratios of 1.2 (95% CI, 1.1–1.4) in dia-
betics and 12.5 (95% CI, 9.5–16.5) in non-
diabetics. Arsenic, mainly trivalent arsenicals
(e.g., arsenite), may induce atherosclerosis
through damage of endothelial cells or
smooth muscle cells by intracellular-reduced
glutathione or through oxidative DNA damage
(Chang et al. 1991; Chiou et al. 1997a; Lynn
et al. 2000; Wu et al. 2001). Further studies are
necessary to test the hypothesis that arsenic
induces renal (Mitchell et al. 2000) and neural
(Brouwer et al. 1992; Mahajan et al. 1992)
damage directly or through angiopathy.
The National Health Insurance Database
used in this study consisted of reimbursement
claims of all patients who had received care
from contracted clinics and/or hospitals at least
once in 1999–2000. Therefore, those who
were not cared for by contracted hospitals or
clinics during the study period were excluded
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Figure 2. Prevalence odds ratios for microvascular diseases among diabetics and nondiabetics in the
endemic area and diabetics in the nonendemic area, compared with nondiabetics in the nonendemic area,
by age and sex. Error bars indicate 95% CI. 
Figure 3. Prevalence odds ratios for macrovascular diseases among diabetics and nondiabetics in the
endemic area and diabetics in the nonendemic area, compared with nondiabetics in the nonendemic
area, by age and sex. Error bars indicate 95% CI. 
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Table 4. Age and gender-adjusted prevalence of various vascular complications among diabetics and
nondiabetics in arseniasis-endemic and nonendemic areas in Taiwan.
Age and gender-adjusted  Prevalence odds ratio in
prevalence (%) endemic area compared
Arseniasis-endemic  Arseniasis-nonendemic with nonendemic area
Disease area area (95% CI) p-Value
Diabetics
Renal diseasea 3.19 1.17 2.78 (2.32–3.33) < 0.001
Retinopathyb 7.88 3.86 2.13 (1.91–2.38) < 0.001
Neurologic disordersc 15.61 2.50 7.21 (6.51–7.97) < 0.001
Peripheral vascular diseased 8.33 6.92 1.22 (1.10–1.35) < 0.001
Cerebrovascular diseasee 21.35 7.77 3.22 (2.99–3.47) < 0.001
Coronary artery diseasef 16.16 7.43 2.40 (2.21–2.61) < 0.001
Nondiabetics
Renal diseasea 0.61 0.41 1.49 (1.33–1.66) < 0.001
Retinopathyb —— g ——
Neurologic disorderc 8.22 0.64 13.97 (13.38–14.58) < 0.001
Peripheral vascular diseased 0.18 0.01 12.50 (9.47–16.48) < 0.001
Cerebrovascular diseasee 8.72 2.49 3.74 (3.62–3.87) < 0.001
Coronary artery diseasef 5.68 4.31 1.34 (1.29–1.39) < 0.001
aICD-9 codes 250.3, 581.8, 582.8, 583.8, 585.0, and 586.0. bICD-9 codes 250.4, 362.0, 362.1, 362.2, and 366.4. cICD-9 codes
250.5, 357.2, 358.1, and 355. dICD-9 codes 250.6, 785.4, and 443.8. eICD-9 codes 430–438. fICD-9 codes 410 and 411–414.
gSample size of the disease cases was too small for valid statistical analysis.from the database. However, more than 96%
of insured people had ever received care from
contracted hospitals and clinics. The preva-
lence estimated in this study was considered
reasonably correct. The disease prevalence
might be overestimated if patients are more
likely to visit clinicians and to be included in
the database than are unaffected people.
Nonetheless, the odds ratio comparing arsenia-
sis-endemic and nonendemic areas would be
valid if the frequencies of visiting clinicians
were the same between two comparison areas.
Considering the rural and urban differences
in lifestyles and disease patterns, residents in the
rural area were considered less likely to develop
cardiovascular diseases as a result of decreased
prevalence of risk factors from dietary intake,
obesity, and physical activity (Singh et al.
1998). However, residents in the arseniasis-
endemic area had a higher prevalence of cardio-
vascular disease despite the fact that the
endemic area was more rural than was the
nonendemic area in Taiwan. Thus, the vascular
effect of ingested arsenic observed in this study
was based on a conservative comparison.
Conclusions
This study demonstrated that residents in the
arseniasis-endemic area had an increased risk of
diabetes and its related vascular diseases com-
pared with those in the nonendemic area. This
study also found a larger contribution of
ingested arsenic than of diabetes on the devel-
opment of microvascular diseases. Future stud-
ies will be directed to mechanistic investigations
of arsenic inducing non-insulin-dependent dia-
betes and atherosclerosis. Risk assessment of
arsenic exposure for diabetes and the related
vascular diseases should be integrated with the
current scheme for cancer risk from arsenic.
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